Press Releases

INCLINE VILLAGE, Nev. , Sept. 9, 2013 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the third quarter ending September 30, 2013 , of approximately $97 million , as compared with actual revenue of $85 million for the third quarter of 2012, an

INCLINE VILLAGE, Nev. , Sept. 4, 2013 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: 3.75% Convertible Senior Notes due May 1, 2015 ( May 2015 Notes), is 157.3700 shares of common stock per $1,000 principal amount or

INCLINE VILLAGE, Nev. , Aug. 8, 2013   /PRNewswire/ --   PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the second quarter and six months ended June 30, 2013 . (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) Royalty revenues for the second quarter of

INCLINE VILLAGE, Nev. , Aug. 1, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its second quarter 2013 financial results for the period ended June 30, 2013 , on Thursday, August 8, 2013 , after market close.

INCLINE VILLAGE, Nev. , July 24, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company has appointed David Montez , CPA, as controller and chief accounting officer.  Mr. Montez's appointment is effective as of today.  (Logo:

--Reicin to Bolster PDL's Expertise in Medical Device Realm--

INCLINE VILLAGE, Nev. , June 12, 2013 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the June 12, 2013 , regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of June 5, 2013 , the record date.

INCLINE VILLAGE, Nev. , June 11, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the second quarter ending June 30, 2013 , of approximately $143 million , as compared with actual royalty revenue of $126 million for the second quarter of

INCLINE VILLAGE, Nev. , June 11, 2013 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that on June 7, 2013 , the Company filed a Notice of Arbitration against Genentech with the American Arbitration Association in Voorhees, New Jersey , alleging, inter alia, that Genentech

INCLINE VILLAGE, Nev. , June 3, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: 2.875% Convertible Senior Notes due February 15, 2015 ( February 2015 Notes) is 176.389 shares of common stock per $1,000 principal amount or

INCLINE VILLAGE, Nev. , May 30, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, will present at the following upcoming conferences. (Logo: 

INCLINE VILLAGE, Nev. , May 9, 2013 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2013 . (Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) Royalty revenues for the first quarter of 2013 increased 19

INCLINE VILLAGE, Nev. , May 2, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2013 financial results for the period ended March 31, 2013 , on Thursday, May 9, 2013 , after market close.

INCLINE VILLAGE, Nev. , April 30, 2013   /PRNewswire/ --   PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company has appointed Peter S. Garcia to the position of vice president, chief financial officer (CFO) and acting chief accounting officer, effective as of May 13 , 2013. 

INCLINE VILLAGE, Nev. , April 22, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) and Avinger, Inc. announced today that they closed a structured financing and royalty transaction on April 18, 2013 , in which PDL will provide Avinger with up to $40 million of financing.  (Logo: